- Home
- Products
- Customized ADCs
- CD19
- Anti-CD19 (B496)-SPP-DM1 ADC
Anti-CD19 (B496)-SPP-DM1 ADC (CAT#: ADC-W-613)
This ADC product is comprised of an anti-CD19 monoclonal antibody (B496) conjugated via a SPP linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- CD19
- Alternative Names
- CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4;
- Target Entrez Gene ID
- 930
- Target UniProt ID
- P15391
- Overview
- Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. This gene encodes a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
- Overview
- Anti-CD19 IgG1 Antibody, B496
- Generic name
- B496
- Species Reactivity
- Mouse
- Name
- SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate)
- Description
- Disulfide Linkers, are extensively exploited as a chemically labile linkage. Since the release of disulfide-linked drugs requires a cytoplasmic thiol cofactor, such as glutathione (GSH). Disulfides maintain stable at physiological pH and only when ADCs are internalized inside cells, the cytosol provides reducing environment including intracellular enzyme protein disulfide isomerase, or similar enzymes, drugs can be released.
- Name
- DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
- Description
- Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-MS4A1 (Afutuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1573)
- Anti-ERBB2 (Trastuzumab)-MMAD ADC (CAT#: ADC-W-408)
- Anti-IGF1-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1236)
- Anti-VEGFA (Ranibizumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1938)
- Anti-FN1 (Radretumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1157)
- Anti-CD33 (clone h2H12) ADC (CAT#: ADC-W-068)
- Anti-C. albicans Hsp90 (Efungumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2196)
- Anti-GD3 (Ecromeximab)-SPDB-DM4 ADC (CAT#: ADC-W-2019)
- Anti-IL4 (Pascolizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1381)
- Anti-APP (Crenezumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-689)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-613. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-2516 | Anti-CD19 (Denintuzumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-779 | Anti-CD19 (Blinatumomab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
ADC-W-324 | Anti-CD19 (clone huB4)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-775 | Anti-CD19 (Taplitumomab paptox)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2519 | Anti-CD19 (Denintuzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
CAT# | Product Name | Linker | Payload |
ADC-W-416 | Anti-ERBB2 (Trastuzumab)-SPP-DM1 ADC | SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-222 | Anti-CD79b (SN8)-SPP-DM1 ADC | SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-460 | Anti-NCAM1 (clone huN901)-SPP-DM1 ADC | SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-625 | Anti-CD22 (10F4v3)-SPP-DM1 ADC | SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-617 | Anti-MS4A1-SPP-DM1 ADC | SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
CAT# | Product Name | Linker | Payload |
ADC-W-541 | Anti-CD44 (clone BIWA 4)-DM1 ADC | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) | |
ADC-W-572 | Anti-ERBB2 (Trastuzumab-Fab)-SPP-DM1 ADC | SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-AA-015 | anti-HIgG(Fc)Fab-N-DM1 ADC | Noncleavable linkers | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-AA-026 | anti-MIgG(Fc)-N-DM1 ADC | Noncleavable linkers | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-496 | Anti-EGFR-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.